Healios (TYO:4593) has added a Contract Development and Manufacturing Organization (CDMO) function to its subsidiary, ProcellCure, according to a Friday filing on the Tokyo Stock Exchange.
The move aims to boost cash flow by offering contract manufacturing services for other companies.
ProcellCure will optimize production for cellular pharmaceutical products, developing Healios' manufacturing capacity. Healios also ended discussions with Saisei Ventures and Mitsubishi UFJ Capital (TYO:8306) regarding previous investments.